| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.6 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.6 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.6 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.014 | 0.6 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |